Vertex Pharmaceuticals, a global biotechnology company that develops medicines for people with serious diseases, announced that it has discontinued Phase 1 development of VX-961.
VX-961 was one of several NaV1.8 inhibitors developed by Vertex for the treatment of pain. Earlier, in 2018, Vertex dropped the development of VX-128 – another NaV1.8 inhibitor. Also, despite the positive Phase 2 data for its lead NaV1.8 inhibitor, VX-150, Vertex has not advanced it into late-phase trials since 2018.
Apparently, Vertex is searching for the best candidate to move into late-stage development. In line with this, Vertex plans to advance an additional molecule into clinical development in the first half of 2020.
Image by Gerd Altmann from Pixabay
